Precision Medicine by David Margulies (Chairman) & Owen McManus (CTO) of Q-State BioSciences | June 19, 2017 Mutations in a single gene, MECP2, can be identified in the vast majority of individuals with Rett Syndrome, yet each person is unique. As in any disease, treatments such as seizure or anxiety medications can be very successful […]

Read On

Discovery Program will be the first application of Q-State stem cell and Optopatch platforms for drug discovery CAMBRIDGE, MA and Brussels, Belgium – April 4, 2017. Q-State Biosciences (“Q-State”) and UCB today announced that they have entered into a multi-year therapeutics discovery collaboration.  The  joint program will employ a precision-medicine approach to the development of […]

Read On

BioCentury journalist Selina Koch profiled Q-State in BioCentury Innovations and presented Q-State Optical electrophysiology platform for assessing neuronal and cardiac cell function in iPS cell-derived disease models.

Read On

Q-State co-founder Kevin Eggan committed his lab research program to determining the mechanisms that cause motor neuron degeneration in Amyotrophic Lateral Sclerosis. He confirmed the promise of stem cell disease modeling and the importance of physiology which both led to this ALS clinical trial.

Read On